8-K: Stoke Therapeutics Initiates Pivotal Phase 3 EMPEROR Study for Dravet Syndrome Treatment Zorevunersen

Stoke Therapeutics has announced the initiation of its Phase 3 EMPEROR study for zorevunersen, a potential disease-modifying therapy for Dravet syndrome, with the first U.S. sites activated in May 2025.

Summary

• Stoke Therapeutics has initiated the Phase 3 EMPEROR study for zorevunersen (STK-001), its lead product candidate for Dravet syndrome, with the first U.S. sites commencing in May 2025.
• Zorevunersen is being developed as a potential first-in-class, disease-modifying therapy for Dravet syndrome, aiming to restore protein expression using the company's proprietary RNA medicine platform, TANGO.
• Prior Phase 1/2a and Open-Label Extension (OLE) studies demonstrated substantial and durable reductions in convulsive seizure frequency, with up to an 87% reduction at Month 8 observed with initial 2 & 3 doses of 70mg followed by 45mg in OLE, alongside ongoing improvements in cognition and behavior as measured by Vineland-3 GSV scores.
• The EMPEROR study is designed as a sham-controlled, 1:1 randomized trial, targeting approximately 150 patients aged 2 to less than 18 years with a confirmed SCN1A gene variant.
• The primary endpoint for the Phase 3 study is the percent change from baseline in major motor seizure frequency at Week 52, with key secondary endpoints including durability of effect and improvements in behavior and cognition.
• Data from the Phase 3 EMPEROR study is anticipated in the second half of 2027.
• Stoke Therapeutics maintains a strategic collaboration with Biogen, granting Biogen exclusive commercialization rights for zorevunersen outside the U.S., Canada, and Mexico, which includes a $165 million upfront payment and potential milestone payments of up to $385 million.
• As of March 31, 2025, the company reported $380 million in cash, cash equivalents, and marketable securities, providing a projected cash runway to mid-2028, which extends beyond the anticipated Phase 3 readout and into launch readiness.

Sentiment

Score: 8

Explanation: The document presents highly positive news regarding the initiation of a pivotal Phase 3 study for its lead candidate, zorevunersen, supported by strong prior clinical data and a robust financial position. The Biogen collaboration further de-risks the program and provides substantial funding. While risks inherent to drug development are present, the overall tone and factual updates are very favorable, indicating significant progress and potential.

Positives

• Initiation of the pivotal Phase 3 EMPEROR study for zorevunersen marks a significant advancement for the company's lead program and potential market entry.
• Compelling clinical data from Phase 1/2a and OLE studies show substantial and durable reductions in convulsive seizure frequency (up to 87% reduction) and ongoing improvements in cognition and behavior in Dravet syndrome patients.
• Zorevunersen has received FDA Breakthrough Therapy Designation, indicating its potential to offer substantial improvement over existing therapies for Dravet syndrome.
• The strategic collaboration with Biogen provides significant non-dilutive funding, including a $165 million upfront payment and potential milestone payments of $385 million, while leveraging Biogen's global commercial expertise.
• A strong financial position with $380 million in cash, cash equivalents, and marketable securities as of March 31, 2025, ensures a cash runway to mid-2028, covering the Phase 3 readout and launch readiness.
• Zorevunersen has been generally well-tolerated across studies, with no clinical manifestations observed for common CSF protein elevations.
• The TANGO platform offers advantages such as selective protein expression, no observed off-target genetic effects, and the ability to control dose level and duration.
• The drug addresses a significant unmet medical need in Dravet syndrome, as current treatments primarily focus on seizure reduction and do not address the underlying disease or associated developmental and cognitive deficits.

Risks

• The company's ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates, including zorevunersen, is uncertain.
• The timing of data readouts and interim and final results of nonclinical and clinical studies may vary.
• The receipt and timing of potential regulatory decisions are subject to uncertainty.
• Positive results observed in early-stage clinical trials may not be replicated in subsequent trials or be predictive of results in later-stage trials.
• The company's ability to fund development activities and achieve development goals, including expectations regarding its collaborations with Acadia Pharmaceuticals and Biogen International, is subject to various factors.
• The company's ability to protect its intellectual property may be challenged.
• Global business, political, and macroeconomic conditions, including inflation, tariffs, interest rate volatility, cybersecurity events, uncertainty with respect to the federal budget, regulatory uncertainty, instability in the global banking system, and volatile market conditions, could negatively impact operations.
• Global events, including public health crises and ongoing geopolitical conflicts such as those in Ukraine and the Middle East, pose risks.
• Regulatory authorities may interpret or weigh the importance of data differently than the company, request additional information, or change their guidance or requirements before or after approval.
• Receiving Breakthrough Therapy Designation does not guarantee faster development or regulatory review or approval, nor does it mean zorevunersen will receive marketing approval.

Future Outlook

Stoke Therapeutics anticipates the data readout from the Phase 3 EMPEROR study of zorevunersen in the second half of 2027. The company plans to continue advancing its TANGO platform, progressing STK-002 for Autosomal Dominant Optic Atrophy (ADOA) and its collaboration with Acadia on SYNGAP1, while also assessing and prioritizing new research targets. The company is financially positioned to fund operations beyond the Phase 3 readout and into launch readiness, with a cash runway extending to mid-2028.

Management Comments

• "Our goal is to restore protein expression by harnessing the body's potential with RNA medicine."
• "Stokes pipeline offers potential first-in-class disease modifying new medicines for diseases caused by protein insufficiency."
• "The EMPEROR Phase 3 study design and dose regimen are aligned with Phase 1/2 and OLE studies."
• "Zorevunersen is positioned to change the treatment of Dravet Syndrome."
• "The company is capitalized beyond Phase 3 readout and into launch readiness."

Industry Context

The announcement highlights Stoke Therapeutics' commitment to developing disease-modifying therapies for severe genetic diseases, specifically Dravet syndrome, an area with significant unmet medical needs where current treatments primarily manage symptoms rather than addressing the underlying cause. This aligns with a broader industry trend towards precision medicine and gene-targeted therapies for rare diseases. The strategic collaboration with Biogen, a major pharmaceutical player, further validates the potential of Stoke's RNA-based approach and underscores the growing interest and investment in the rare disease and genetic medicine markets.

Comparison to Industry Standards

• Dravet syndrome affects approximately 38,000 patients across 7 major markets, representing a substantial patient population for a rare disease, which is attractive for pharmaceutical development compared to ultra-rare conditions.
• Current standard of care for Dravet syndrome, including multiple anti-seizure medications, primarily focuses on seizure reduction, leaving a significant gap in addressing the syndrome's broader developmental and cognitive deficits, which zorevunersen aims to fill as a disease-modifying therapy.
• The reported median 87% reduction in convulsive seizure frequency at Month 8 in OLE studies for zorevunersen, on top of standard of care, represents a compelling improvement compared to natural history data where patients on best available anti-seizure medicines showed no meaningful improvement in convulsive seizure frequency.
• The initiation of a Phase 3 study specifically designed to assess disease modification is a pioneering effort in Dravet syndrome, as no other disease-modifying medicines are currently available, setting a new benchmark for therapeutic development in this indication.
• The Biogen collaboration, with its $165 million upfront payment and potential $385 million in milestones, is a substantial deal for a company of Stoke's size, comparable to other significant partnerships seen in the rare disease and gene therapy space, validating the potential of zorevunersen.

Stakeholder Impact

• Shareholders: Positive impact due to the advancement of the lead clinical program into Phase 3, strong financial position, and validation through the Biogen collaboration, potentially leading to increased company valuation.
• Patients (Dravet Syndrome): Significant potential for a first-in-class, disease-modifying treatment that could address not only seizures but also cognitive and behavioral deficits, offering hope for improved quality of life.
• Caregivers/Families: Potential for reduced burden and improved outcomes for their loved ones with Dravet syndrome, as the therapy aims to address the underlying cause of the disease.
• Employees: Positive impact from continued progress in clinical development and financial stability, supporting job security and potential growth opportunities within the company.
• Regulatory Authorities: Ongoing discussions and submissions related to the Phase 3 study and potential future marketing approval, requiring continued collaboration and adherence to regulatory guidelines.

Next Steps

• Drive enrollment in the Phase 3 EMPEROR study for zorevunersen.
• Drive greater awareness and understanding of zorevunersen's potential for disease modification in Dravet syndrome.
• Continue progress on STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
• Continue progress with Acadia on the SYNGAP1 program.
• Assess and prioritize new research targets for the TANGO platform.
• Anticipate Phase 3 data readout in the second half of 2027.

Key Dates

Recommendation

Keywords

Stoke Therapeutics, Dravet Syndrome, Zorevunersen, STK-001, Phase 3, EMPEROR study, Clinical Trial, Genetic Epilepsy, SCN1A gene, RNA medicine, TANGO platform, Biogen collaboration, Breakthrough Therapy Designation, Neurodevelopmental disorders, Rare diseases, Biotechnology, Pharmaceuticals, Epilepsy treatment, STOK